FBIOX — Select Biotechnology Portfolio
Data updated: 2026-07-24
FBIOX — Select Biotechnology Portfolio. United States Multi-Cap / All-Cap Blend / Core Health Care Equity. Holdings, fees, performance and SEC filings.
FBIOX Fund Overview
FBIOX — Select Biotechnology Portfolio is a US mutual fund managed by Fidelity Select Portfolios, categorised as United States Multi-Cap / All-Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Fidelity Select Portfolios
- Category: United States Multi-Cap / All-Cap Blend / Core Health Care Equity
- Assets under management: $5.27B
- 1-year return: 55.7%
- Ticker: FBIOX
- SEC CIK: 0000320351
- SEC series ID: S000007486
- Share class ID: C000020460
FBIOX Holdings
Top 10 holdings of Select Biotechnology Portfolio by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Krystal Biotech, Inc. | 10.58% |
| Abbvie, Inc. | 9.22% |
| Amgen, Inc. | 6.53% |
| Gilead Sciences, Inc. | 4.82% |
| Fidelity Revere Street Trust | 3.35% |
| Alnylam Pharmaceuticals, Inc. | 2.93% |
| Praxis Precision Medicines Inc. | 2.47% |
| Insmed, Inc. | 2.25% |
| Argenx SE | 2.25% |
| Ascendis Pharma A/s | 2.04% |
FBIOX Portfolio Allocation
Asset-class allocation of Select Biotechnology Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 3.5% |
FBIOX Performance
Total returns for FBIOX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 6.2% |
| 1 year | 55.7% |
| 3 years (annualised) | 18.9% |
| 5 years (annualised) | 6.7% |
FBIOX Risk Information
Risk metrics for FBIOX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 12.6%
FBIOX Costs and Fees
FBIOX costs about $62 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.62%
- Gross expense ratio: 0.62%
- Portfolio turnover: 45%
- Brokerage commissions: 3.29 bps of average net assets (SEC N-CEN)
FBIOX Cashflows
Over the 12 months to 2026-05, Select Biotechnology Portfolio had net outflows of $59.49M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-05 | −$66.21M |
| 2026-04 | $156.91M |
| 2026-03 | −$68.30M |
| 2026-02 | −$39.35M |
| 2026-01 | −$37.63M |
| 2025-12 | $116.04M |
FBIOX Debt Constituents
No individual debt constituents are reported in Select Biotechnology Portfolio's latest SEC N-PORT filing.
FBIOX Prospectus and SEC Filings
Official Select Biotechnology Portfolio filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-04-24
- Prospectus (485BPOS) — filed 2025-04-24
- Prospectus (485BPOS) — filed 2024-04-24
- Portfolio holdings (N-PORT) — filed 2026-07-24
- Portfolio holdings (N-PORT) — filed 2026-04-24
- Portfolio holdings (N-PORT) — filed 2026-01-23
- Annual census (N-CEN) — filed 2026-05-12
- Annual census (N-CEN) — filed 2025-05-13
Related Funds
Other United States Multi-Cap / All-Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.